Tag: provides

Deep learning model provides rapid detection of stroke-causing blockages

A sophisticated type of artificial intelligence (AI) called deep learning can help rapidly detect blockages in the arteries that supply blood to the head, potentially speeding the onset of life-saving treatment, according to a study published in Radiology. Large vessel occlusions are blockages in the arteries that supply oxygenated blood to the brain. These occlusions

New discovery provides hope for improved multiple sclerosis therapies

Scientists from Trinity College Dublin have made an important discovery that could lead to more effective treatments for people living with multiple sclerosis (MS) and other autoimmune diseases such as psoriasis and rheumatoid arthritis. Their work highlights the significant potential of drugs targeting a specific immune molecule (IL-17) implicated in MS. The scientists, led by

Immunotherapy for peanut allergy provides protection but not a cure

Researchers from King’s have found that a potential treatment for peanut allergy provides some degree of protection but does not cure an allergic patient and this could explain why allergic reactions are still observed during treatment. In the study, published today in the Journal of Allergy and Clinical Immunology, researchers tested samples from patients who

Small Trial Provides New Hope Against Parkinson’s Disease

FRIDAY, March 1, 2019 — It may be possible to restore brain cells damaged by Parkinson’s disease and reverse a patient’s condition, something no current treatment can do, according to British researchers who conducted potentially groundbreaking clinical trials. They cautioned the trial was small — just 41 patients — and the research is still in

Immunotherapy provides long-term survival benefit: Further evidence in lung cancer

Further evidence that immunotherapy provides long-term survival benefit for patients with lung cancer was presented today at ELCC 2018 (European Lung Cancer Congress) in Geneva, Switzerland. Researchers presented the three-year survival results of the randomised phase 2 POPLAR trial in second line, which is the longest follow-up reported to date with anti-programmed death ligand 1